CLB Core Laboratories Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * DEMSHUR DAVID M	2. Issuer Name and Ticker or Trading Symbol CORE LABORATORIES N V [ CLB ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Executive Officer
(Last)          (First)          (Middle) 6316 WINDFERN ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 12/31/2019
(Street) HOUSTON, TX 77040 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/31/2019		M		59100	A	$0.00	385118	D
Common Shares	12/31/2019		F		19274	D	$37.67	365844	D
Common Shares								68530	I	401(k) Plan

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Shares	$0.00	12/31/2019		M			59100	(1)	(1)	Common Shares	59100	$0.00	0	D

Explanation of Responses:

(1)

The shares vesting were awarded as restricted performance shares in February 2017 as reported in the Form 4 filing on February 16, 2017. This filing states that 50% of the restricted performance shares will vest at the end of the Performance Period if the Company is in the top 50th ROIC percentile among a Bloomberg Peer Group(BPG), 100% of the award will vest if the Company is in the top 75th ROIC percentile of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG. The Company was the top performing ROIC company as of the end of the performance period and as such the performance criteria and all requirements for full vesting have been met and thus the shares granted in February 2017 vested on December 31, 2019, at the conclusion of the performance period.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
DEMSHUR DAVID M 6316 WINDFERN ROAD HOUSTON, TX 77040	X		Chief Executive Officer

Signatures
/s/ Mark Elvig, Attorney-in-Fact		1/3/2020
**Signature of Reporting Person		Date